Eli Lilly and Company (NYSE: LLY) announces the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. “This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,” said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. “We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.”
Read the full article: Lilly Completes Acquisition of Verve Therapeutics to Advance One-Time Treatments for People with High Cardiovascular Risk //
Source: https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk-302513948.html